The PI3K/Akt pathway mediating FOXO1 binding to the promoter of MALAT1 could be a mechanism for MALAT1 inducing EMT and reducing trastuzumab sensitivity in HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.